Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Founded in 1992, the company’s portfolio includes FDA-approved therapies for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, and endometriosis and uterine fibroids. Key commercial products include INGREZZA (valbenazine), marketed as DYSVAL in Japan and REMLEAS in select Asian markets, and CRENESSITY (crinecerfont). The company collaborates with AbbVie on elagolix for endometriosis and uterine fibroids, where AbbVie retains global commercialization rights. Neurocrine’s pipeline features late-stage candidates such as osavampator for major depressive disorder and direclidine for schizophrenia, alongside early-phase compounds across small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. The company serves patients in the U.S., Japan, and select Asian markets, utilizing a specialized sales force and third-party logistics providers for distribution.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage neurocrine.com
Sector Healthcare IR page neurocrine.com/investors
Tags
neurology, psychiatry, endocrinology, rare diseases, small molecules, peptides, antibodies, gene therapies, tardive dyskinesia, huntington's disease, congenital adrenal hyperplasia, endometriosis, INGREZZA, valbenazine, CRENESSITY, crinecerfont, DYSVAL, REMLEAS, elagolix, osavampator, NBI-1065845, direclidine, NBI-1117568, AbbVie, Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited
Press page —

Metrics

Valuation  
Market cap $ 16.682B
Market cap (USD) $ 16.682B
P/E 24.40
PEG 0.53
P/BV 4.30
P/S 4.51
P/OCF 15.65
P/FCF 16.04
Dividend yield —
Turnover / mcap —
Returns  
ROE 16.4%
ROI 16.2%
ROIC 14.2%
Profit margin 16.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 45.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 97
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 2.861B 2.355B 1.887B 1.489B 1.134B 1.046B 788.087M 451.24M 161.626M 15M 19.769M 0 2.919M 53.14M 77.413M 33.501M — — — 39.234M 123.889M 85.176M 139.078M 18.045M 41.242M —
Net profit 478.6M 341.3M 249.7M 154.5M 89.6M 407.3M 37.012M 21.111M -142.542M -141.09M -88.929M -60.542M -46.09M 5.025M 37.571M -7.968M -51.038M -88.613M -207.299M -107.205M -22.191M -45.773M -30.256M -94.536M -36.91M -28.808M
Free cash flow 748.7M 557.2M 361.6M 322.9M 233.1M 217.6M 137.306M 76.552M -101.271M -110.289M -39.931M -48.752M -30.152M -36.265M -1.431M 49.628M -53.13M -75.495M -59.958M -102.444M -38.029M -153.135M -13.311M -84.665M -25.661M -21.085M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 141.83 136.5 131.76 119.44 85.17 95.85 107.49 71.41 77.59 38.7 56.57 22.34 9.34 7.48 5.96 7.65 2.65 3.4 — 19.98 — — — — — —
Price performance 12m 0.04 0.04 0.1 0.4 -0.11 -0.11 0.51 -0.08 1 -0.32 1.53 1.39 0.25 0.26 -0.22 1.88 -0.22 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 0.00 31.1M 56.2M 127M 157M 186M 350M 439M 479M 687M
↳ YoY growth +80.7% +125.1% +24.1% +18.1% +88.7% +25.5% +9.1% +43.4%
↳ 5y CAGR +17.2% +376.1% +62.3% +50.8% +30.5% +34.3%
Lease liabilities (USD) — — 0.00 95M 105M 122M 111M 290M 496M 471M
Cash and deposits (USD) 83.3M 255M 142M 112M 187M 341M 263M 251M 233M 713M
Intangible assets (USD) — — — — — 0.00 37.2M 35.5M 36.5M 4.7M
Right-of-use assets (USD) — — 0.00 74.4M 82.8M 97.2M 87M 277M 509M 455M
Cash flow detail
Operating cash flow (USD) -106M -94.3M 101M 152M 229M 257M 339M 390M 595M 783M
Purchases of property, plant and equipment (USD) -4.11M -6.94M -24.8M -14.7M -10.9M -23.4M -16.5M -28.3M -38.2M -34M
Change in receivables (cash effect) (USD) 0.00 -31.1M -25.1M -69.2M -30.5M -28.4M -162M -89.3M -39.8M -211M
Change in inventories (cash effect) (USD) 0.00 -1.02M -3.52M -6.42M -10.7M -2.5M -2.6M 5.4M -19.1M -15.3M
Change in payables (cash effect) (USD) 4.4M 27.3M 24.2M 54M 26.9M 56.8M 115M 64.3M 29M 160M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -300M -168M
Interest paid (cash effect) (USD) 0.00 -6.24M -11.6M -11.6M -11.6M -8.6M -6.6M -3.8M -1.6M 0.00
Income taxes paid (cash effect) (USD) 0.00 0.00 0.00 -507,000 -15.3M -5.1M -14.4M -51.5M -218M -81.4M
Share-based compensation (USD) 28.5M 42.5M 58.1M 75.3M 100M 134M 173M 194M 196M 218M
Operating cash flow before change in receivables (USD) -106M -63.2M 126M 221M 259M 285M 502M 479M 635M 993M
Free cash flow (OCF - PPE - intangibles) (USD) -110M -101M 76.6M 137M 218M 233M 323M 362M 557M 749M
Income detail
Research and development expense (USD) 94.3M 122M 161M — 275M 328M 464M 565M 731M 1.02B
↳ 5y CAGR +25.0% +26.8% +32.5% +27.5% +28.3% +30.7% +28.6% +29.9%
Total comprehensive income (USD) -140M -144M 21M 40.4M 408M 86.1M 148M 265M 340M 486M
Comprehensive income to owners (USD) -140M -144M 21M 40.4M 408M 86.1M 148M 265M 340M 486M
Reported Feb 13, 2018 Feb 13, 2018 Feb 7, 2020 Feb 7, 2020 Feb 9, 2023 Feb 9, 2023 Feb 10, 2025 Feb 10, 2025 Feb 10, 2025 Jul 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/5/26

Download PDF version

  • Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0

  • A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline

SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA® (valbenazine) capsules.1 A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective. The findings will be presented at the Neuroscience Education Institute Fall Congress 2026 taking place Nov. 5-8 in Colorado Springs, Colo.

"Tardive dyskinesia is characterized by involuntary movements, but the patient experience extends beyond movement severity alone," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "These findings add to an extensive and established body of evidence demonstrating that INGREZZA not only reduces uncontrolled movements but also that patients reported meaningful improvements in their daily functioning and quality of life with treatment."

Survey Findings Show Fewer Work and School Disruptions After Starting INGREZZA:

The quantitative survey was conducted online in the United States by Ipsos on behalf of Neurocrine from Jan. 15 to Feb. 17, 2026. It included 100 individuals: 70 adults diagnosed with TD by a healthcare provider who were receiving or previously received treatment with a vesicular monoamine transporter 2 (VMAT2) inhibitor, including INGREZZA, and 30 nonprofessional care partners.

Building on previously reported findings from the same survey showing the substantial impact of TD on work, school, and productivity prior to treatment, the new analysis provides insights into patient experiences following treatment, including among patients treated with INGREZZA.

Key findings among respondents with TD taking INGREZZA (n=63)*:

  • Fewer work and school disruptions: 57% reported disruptions to work or school before treatment, compared with 21% after starting treatment.

  • Less self-consciousness: 68% reported feeling self-conscious in a workplace or school setting before treatment, compared with 35% after starting treatment.

  • Fewer missed days: The average number of missed days of school and work reported per month decreased from 5.6 before treatment to 2.0 after starting treatment.

  • Improved productivity: 51% of respondents reported improvements in productivity at work or school after starting treatment.

Across the broader survey population (n=100), a majority of whom received treatment with INGREZZA, respondents strongly agreed that VMAT2 inhibitor treatment led to improvements in quality of life and daily activities (94%), daily functioning and independence (93%), overall happiness and health (93%), and the ability to participate in hobbies and interests (91%).

KINECT-PRO Analysis Shows Clinically Meaningful Patient-Reported Improvement with INGREZZA:

In a separate Neuroscience Education Institute (NEI) congress presentation, a post-hoc analysis of KINECT-PRO provided a deeper look at patient-reported improvement with INGREZZA. Previous KINECT-PRO findings reported by patients on INGREZZA showed clinically meaningful improvements in TDIS total score, regardless of underlying psychiatric diagnosis or TD movement severity, including among patients with mild movements. The new analysis evaluated the proportion of participants who met stringent and meaningful thresholds for improvement in TDIS total score and examined changes within individual TDIS areas among participants who reported impacts in those respective areas at baseline.

KINECT-PRO is currently the only study to assess the effects of a VMAT2 inhibitor (INGREZZA) on quality of life and functionality using multiple validated patient-reported outcomes (PROs), including the TDIS. The TDIS includes 11 questions assessing six physical and socio-emotional areas: mouth/throat function, dexterity, mobility, emotional, pain, and social.

Key results include:

  • Among participants with available data at Week 24 (n=45), 82.2% reported any improvement (≥1-point reduction) in TDIS total score, while 62.2% reported improvement consistent with the minimal clinically important difference (MCID) threshold for TDIS total score improvement (≥4-point reduction).

  • INGREZZA is the only FDA-approved treatment for TD with clinically meaningful improvements in TD impacts using an MCID threshold that is aligned with FDA guidance for PRO reporting.

  • Among participants reporting an impact in a given TDIS area at baseline, mean percentage decreases in TDIS scores, indicating improvement, ranged from 40% to 70% across all six areas at Week 24.

*Post-treatment employment-related findings were based on small analysis populations of fewer than 100 respondents with TD who met the study's employment criteria. Exercise caution when interpreting results.

11/3/26

Download PDF version

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Springs, Colo. Through a special industry-sponsored session, "Inspired by Patients, Driven by Science: The Neurocrine Story," Neurocrine will take attendees behind the science, challenges, and breakthroughs that have shaped the company over more than three decades and explore how those experiences are informing its vision for the future of neuroscience and the treatment of neuropsychiatric conditions. Additionally, the company will share poster presentations highlighting the breadth of its expanding work in neuropsychiatry, including major depressive disorder and schizophrenia, alongside continued research in tardive dyskinesia.

"We're proud to share more of Neurocrine's scientific journey with the neuroscience community at NEI, including the challenges and lessons that have shaped our approach over more than three decades and the work underway today across psychiatry," said Dimitri E. Grigoriadis, Ph.D., Distinguished Scholar, Neurocrine Biosciences. "Our progress has always been grounded in following the science, learning along the way, and staying focused on the needs of patients. We look forward to sharing new insights across major depressive disorder, schizophrenia and tardive dyskinesia, and to continuing to build on that foundation as we pursue new medicines for people living with serious neuropsychiatric conditions."

Details of Neurocrine's Industry-Sponsored Session:

**Title:**Inspired by Patients, Driven by Science: The Neurocrine Story Presenters: Dimitri E. Grigoriadis, Ph.D., Distinguished Scholar, Neurocrine Biosciences and Christopher F. O'Brien, M.D., Former Chief Medical Officer, Neurocrine Biosciences Date/Time: November 6, from 6:45-7:45 p.m. MT

Details of Neurocrine's Poster Presentations at NEI (all times are MT):

**Major Depressive Disorder (MDD):**An analysis of glutamatergic dysfunction in MDD, as well as a qualitative study examining patient experiences with cognitive impairment and real-world antidepressant treatment patterns.

Title: Beyond Monoamines: The Role of Glutamatergic Signaling and AMPA Receptor Modulation in Major Depressive Disorder**(Poster Presentation #130)**Authors: Samantha E. Yohn, Ph.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Cognitive Impairment in Major Depressive Disorder: A Patient-Identified Priority for Functional Recovery**(Poster Presentation #39)**Authors: Chris Wallick, Pharm.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Major Depressive Disorder Treatment Sequencing, Continuity and Combinations by Healthcare Provider Specialty in Adults Treated with Antidepressants (Poster Presentation #140) Authors: Swarnali Goswami, Ph.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

**Schizophrenia:**An analysis of cardiometabolic comorbidities following initiation of oral atypical antipsychotics.

Title: Cardiometabolic Comorbidity Development and its Pharmacologic Treatment Following Oral Atypical Antipsychotic Initiation in Adults with Schizophrenia (Poster Presentation #146) Authors: Spencer Cheng, Pharm.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

**Tardive Dyskinesia (TD):**Findings on the impact of TD on employment and productivity, alongside new analyses from KINECT-PRO™, the first and only study to evaluate the effects of a VMAT2 inhibitor (INGREZZA®) on quality of life and functioning in TD patients across multiple validated PRO measures.

Title: Survey Results Demonstrate Substantial Burden of Tardive Dyskinesia on Employment/Productivity and the Positive Effects of FDA-Approved Treatments **(Poster Presentation #145)**Authors: M. Mercedes Perez-Rodriguez, M.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Valbenazine Meaningfully Improves Socio-Emotional and Physical Impacts on the Tardive Dyskinesia Impact Scale (TDIS™): Post Hoc Analyses of KINECT-PRO™ Data **(Poster Presentation #144)**Authors: Ashok Parameswaran, M.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Evidence-Based Recommendations for Treating Tardive Dyskinesia with a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor **(Poster Presentation #69)**Authors: Amita Patel, M.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Once-Daily Valbenazine Demonstrates Greater and More Predictable Exposure Than Deutetrabenazine Extended Release: Results from a PET Study in Healthy Male Adults **(Poster Presentation #68)**Authors: Daniel Albrecht, Ph.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Symptomatic Remission of Tardive Dyskinesia in Two Distinct Studies of Once-Daily Valbenazine: Results from the KINECT® 4 and KINECT-PRO™ Clinical Trials **(Poster Presentation #52)**Authors: Christoph Correll, M.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

Title: Association between Valbenazine Initiation and Antipsychotic Discontinuation among Medicare Beneficiaries with Tardive Dyskinesia **(Poster Presentation #33)**Authors: Rimal Bera, M.D., et al. Date/Time: November 7, from 2:40-3:40 p.m.

About Major Depressive DisorderMajor depressive disorder (MDD) is a serious disorder characterized by a persistently depressed mood, loss of interest, poor concentration, and decreased energy, among other symptoms. According to the World Health Organization, MDD is one of the leading causes of disability, is a serious condition that presents an increased risk of suicide and self-harm, and is associated with increased all-cause mortality rates. More than 21 million people in the U.S. live with MDD and it is estimated that roughly a third of those do not respond to available antidepressants.

About SchizophreniaSchizophrenia is a serious and complex syndrome with heterogeneous symptoms. The World Health Organization estimates that the disorder impacts approximately 24 million people worldwide. Annual associated costs for schizophrenia are estimated to be more than $150 billion in the U.S. As one of the leading causes of disability worldwide, it often results in significant emotional and functional burden for those who experience symptoms, as well as their family and friends. This chronic and disabling mental health condition is thought to result from a complex interplay of genetic and environmental risk factors. Traditional treatment approaches for schizophrenia rely on the use of antipsychotic medications that can lead to considerable short- and long-term health impacts.

About Tardive Dyskinesia Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S.

About the KINECT-PRO™ Phase 4 Study The KINECT-PRO™ Phase 4, open-label study was designed to evaluate patient-reported outcomes on the use of INGREZZA® (valbenazine) capsules in a tardive dyskinesia (TD) patient population reflective of real-world clinical practice. Participants had at least mild TD, were aware of and experiencing at least mild distress from their abnormal, involuntary movements, and had a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression. The KINECT-PRO study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg, or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic and clinical characteristics of the participants were broadly similar to those of the KINECT® 3 and KINECT® 4 studies.

About the Tardive Dyskinesia Impact Scale The Tardive Dyskinesia Impact Scale (TDIS™) is a novel, psychometrically validated patient-reported outcome measure in TD. It was developed by Neurocrine Biosciences from qualitative studies and Phase 3 trials of INGREZZA for the treatment of TD (KINECT® 3 and KINECT® 4) as a comprehensive measure of impact and burden of TD from a patient's perspective. The TDIS consists of 11 questions evaluating physical and socio-emotional impact. Six domains are assessed: mouth/throat, dexterity, mobility, pain, social, and emotional. The TDIS allows people with TD to rate how their symptoms affect daily activities and how their uncontrollable movements make them feel. The questionnaire captures relevant information about the impact of TD to provide a more holistic assessment of the condition. Validation of this scale was published in the Journal of Patient-Reported Outcomes.

About INGREZZA® (valbenazine) Capsules and INGREZZA® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration.

INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements.

INGREZZA is studied across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules.

Important Information Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with:

  • movements in the face, tongue or other body parts that cannot be controlled (tardive dyskinesia).

  • involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.

It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior or have thoughts of hurting yourself.

Do not take INGREZZA or INGREZZA SPRINKLE if you:

  • are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE.

INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:

  • Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue or throat, or other areas of your skin, trouble with swallowing or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema.

  • **Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation).**Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE.

  • **Heart rhythm problems (QT prolongation).**INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness or fainting or feeling like you are going to faint.

  • **Neuroleptic Malignant Syndrome (NMS).**NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating or very fast or uneven heartbeat.

  • Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors) or falls.

Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days.

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia aresleepiness and tiredness.

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash and trouble getting to sleep or staying asleep.

These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg and 80 mg capsules.

Please see fullPrescribing Informationincluding Boxed Warning, and Medication Guide.

About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, KINECT and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. TDIS and KINECT-PRO are trademarks of Neurocrine Biosciences, Inc.

Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding our business strategy, objectives, and future development plans, including the advancement of our psychiatry pipeline and our research in major depressive disorder, schizophrenia, and tardive dyskinesia; our planned presentations and discussions at the 2026 Neuroscience Education Institute (NEI) Fall Congress, and the interpretation and potential relevance of the research and data to be presented; the potential benefits to be derived from our products and products candidates; and the value our products and/or our product candidates may be bring to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: risks and uncertainties as to whether the findings from the studies and analyses to be presented will be replicated in additional studies or will be predictive of clinical outcomes in subsequent studies or clinical practice; risks and uncertainties associated with our business and finances in general; risks and uncertainties associated with the commercialization of our products; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-spotlight-its-scientific-journey-and-growing-neuropsychiatry-pipeline-at-2026-nei-fall-congress-302928380.html

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Media: Liz Reynolds, 1-818-749-8778, [email protected]; Investors: Todd Tushla, 1-858-617-7143, [email protected]

Resources

Email Alerts

2025 Annual Report

2026 Proxy Statement

Webcasts & Presentations

11/2/26

Download PDF version

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion

INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026.

"Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company. Looking ahead to 2027, we see meaningful opportunities for continued growth across INGREZZA, CRENESSITY® (crinecerfont) and VYKAT® (diazoxide choline) XR, alongside multiple important clinical milestones, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia."

Total Revenue Highlights

| | Three Months Ended September 30, | | |

| (unaudited, in millions, except per share data) | 2026 | | 2025 | | YoY Growth |

| Revenues: | | | | | |

| INGREZZA Net Product Sales | $ 801 | | $ 687 | | 17 % |

| CRENESSITY Net Product Sales | 211 | | 98 | | 115 % |

| VYKAT XR Net Product Sales | 107 | | — | | NM |

| Other Revenues | 4 | | 10 | | NM |

| Total Revenues | $ 1,123 | | $ 795 | | 41 % |

  • Total revenues for the third-quarter 2026 were $1.1 billion, compared with $795 million in the prior-year period representing 41% year-over-year growth.

  • INGREZZA third-quarter 2026 net product sales were $801 million, representing 17% growth year-over-year. Results reflected double-digit volume growth, with record TRx and NRx supported by strong demand and high rates of persistency.

  • INGREZZA full year 2026 guidance was increased from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion.

  • CRENESSITY third-quarter 2026 net product sales were $211 million, driven by steady new patient demand and high rates of persistency with approximately 80% reimbursement for dispensed prescriptions.

  • VYKAT XR third-quarter 2026 net product sales were $107 million, driven by steady and consistent patient demand and persistency.

Recent Clinical and Corporate Developments

  • Announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. This follows the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-'2118, a potential first-in-class CRF2 peptide agonist. Initial clinical data from both programs will inform the development of a novel co-formulated combination therapy, including the optimal ratio of the two agents. NBIP-'2118 will also be evaluated independently as a potential standalone therapy for obesity.

  • Announced the initiation of a Phase 2 clinical study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-'567, an investigational M1/M4 (M1-preferring) selective muscarinic agonist being developed as an adjunctive therapy for cognitive impairment in Alzheimer's disease.

  • Announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA capsules resulted in substantial and sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia (TD) movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline TD movement severity, including among participants with clinician-rated mild TD movements. The manuscript appears in CNS Spectrums.

  • Presented research advancing the understanding of Prader-Willi syndrome and real-world experience with VYKAT XR at the Foundation for Prader-Willi Research Symposium & Family Conference.

  • Announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the Company's executive management team as Chief Medical Officer (CMO).

  • Company to host R&D Day in New York on December 15, 2026.

Third-Quarter 2026 Financial Results

| | Three Months Ended September 30, |

| (unaudited, in millions, except per share data) | 2026 | | 2025 |

| Total Revenues | $ 1,123 | | $ 795 |

| | | | |

| GAAP Cost of Revenues | $ 27 | | $ 13 |

| Non-GAAP Cost of Revenues | $ 20 | | $ 13 |

| | | | |

| GAAP Research and Development (R&D) | $ 352 | | $ 250 |

| Non-GAAP R&D | $ 317 | | $ 228 |

| | | | |

| GAAP Selling, General, and Administrative (SG&A) | $ 366 | | $ 292 |

| Non-GAAP SG&A | $ 327 | | $ 259 |

| | | | |

| GAAP Net Income | $ 207 | | $ 210 |

| GAAP Earnings Per Share – Diluted | $ 1.96 | | $ 2.04 |

| | | | |

| Non-GAAP Net Income | $ 347 | | $ 222 |

| Non-GAAP Earnings Per Share – Diluted | $ 3.29 | | $ 2.17 |

| | | | |

| (unaudited, in millions) | September 30, 2026 | | December 31, 2025 |

| Total Cash, Cash Equivalents, and Marketable Securities | $ 790 | | $ 2,543 |

  • Third-quarter 2026 GAAP net income and earnings per share were $207 million and $1.96, respectively, compared with $210 million and $2.04, respectively, for third-quarter 2025.

  • Third-quarter 2026 Non-GAAP net income and earnings per share were $347 million and $3.29, respectively, compared with $222 million and $2.17, respectively, for third-quarter 2025.

  • A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3 at the end of this press release.

  • Third-quarter 2026 GAAP and Non-GAAP net income compared with third-quarter 2025 were primarily driven by:

  • Higher net product sales of $329 million.

  • Third-quarter 2026 GAAP operating expenses included certain expenses associated with the acquisition of Soleno Therapeutics, Inc. (Soleno), which closed in May 2026, and are excluded from Non-GAAP operating expenses.

  • Increased R&D expense in support of an expanded and advancing pre-clinical and clinical portfolio included investments in the osavampator Phase 3 program in major depressive disorder (MDD) and the muscarinic franchise, including the direclidine Phase 3 program as a potential treatment for adults with schizophrenia. Development milestone expense included in R&D was $10 million and $1 million, respectively, for the third quarter 2026 and 2025.

  • Increased SG&A expense primarily reflected continued investment in our commercial organization, included the expansion of our INGREZZA and CRENESSITY sales teams in the first quarter of 2026 and for support of VYKAT XR following the acquisition of Soleno, which closed in May 2026.

  • Third-quarter 2026 includes $52 million loss from changes in fair values of equity investments, compared with a gain of $31 million for third quarter 2025 (Non-GAAP adjustment)

  • At September 30, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $790 million.

Full Year 2026 Financial Guidance

| (dollars in millions) | Prior | | Updated |

| INGREZZA Net Product Sales 1 | $2,825 - $2,875 | | $2,900 - $2,925 |

| | | | |

| GAAP R&D 2 | $1,275 - $1,325 | | No Change |

| Non-GAAP R&D 2, 3 | $1,140 - $1,190 | | No Change |

| | | | |

| IPR&D 4 | $23 | | $34 |

| | | | |

| GAAP SG&A 5 | $1,575 - $1,600 | | $1,540 - $1,560 |

| Non-GAAP SG&A 3, 5 | $1,325 - $1,350 | | $1,290 - $1,310 |

| | | | |

| GAAP Amortization of Acquired Intangible Assets 6 | $85 - $90 | | No Change |

  • INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.

  • R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and includes approximately $33 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve.

  • Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based compensation expense of approximately $115 million in R&D and $170 million in SG&A, including approximately $58 million related to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction, and acquisition, integration and divestiture-related expenses of approximately $95 million. Non-cash stock-based compensation expense for performance-based equity awards is included in guidance once the predefined performance-based criteria for vesting is achieved or deemed probable to achieve.

  • IPR&D guidance represents completed collaboration and licensing arrangements.

  • SG&A guidance reflects expense for ongoing commercial initiatives, including the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth and the launch of CRENESSITY and VYKAT XR.

  • In connection with the acquisition of Soleno, the Company recorded approximately $2.2 billion of intellectual property related to VYKAT XR to the balance sheet, which will be amortized over an expected life of 16 years.

Conference Call and Webcast Today at 4:30 PM Eastern TimeNeurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the live conference call by dialing 800-347-6865 (US) or 203-518-9757 (International) using the conference ID: NBIX. The webcast and accompanying slides can also be accessed at approximately 4:30 p.m. Eastern Time on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine BiosciencesNeurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. VYKAT is a registered trademark of Soleno Therapeutics, Inc.

Non-GAAP Financial MeasuresIn addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following Non-GAAP financial measures: Non-GAAP cost of revenues, Non-GAAP R&D expense, Non-GAAP SG&A expense, Non-GAAP other income (expense), net, Non-GAAP net income and earnings per share. When preparing the Non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these Non-GAAP financial measures exclude: non-cash stock-based compensation expense, amortization expense related to acquired intangible assets, amortization expense related to acquisition-date inventory fair value step-up, stock based compensation expense related to the acceleration of vesting of equity awards for Soleno employees, changes in fair value of equity investments, acquisition-related transaction and integration costs, gains on sales of businesses, net of transaction costs, other divestiture-related transaction costs, changes in foreign currency exchange rates and certain adjustments to income tax expense. These Non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these Non-GAAP financial measures are useful to investors because they help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these Non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&D and SG&A expenses on both a GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to Non-GAAP financial results is included in the attached financial information.

Forward-Looking StatementsIn addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully commercializing CRENESSITY and VYKAT XR; our financial and operating performance, including our future revenues, expenses, or profits; our full year 2026 financial guidance; our acquisition of Soleno Therapeutics, including the prospective benefits of the acquisition, and our strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to our future financial results, growth potential and anticipated product portfolio in connection with the acquisition; our collaborative partnerships; clinical and scientific data updates for our products and product candidates, including observations regarding clinical outcomes, safety, and tolerability; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general; risks and uncertainties associated with the commercialization of our products; risks related to our ability to realize the anticipated benefits of the acquisition of Soleno Therapeutics, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that we will not be able to integrate Soleno Therapeutics' business successfully or that such integration may be more difficult, time-consuming or costly than expected, disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with employees, customers, suppliers, other business partners or governmental entities, unknown or inestimable liabilities, the risk of litigation and/or regulatory actions related to the acquisition, and the degree and pace of market uptake of VYKAT XR; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.

| TABLE 1 |

| |

| NEUROCRINE BIOSCIENCES, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF INCOME |

| (unaudited, in millions, except per share data) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues: | | | | | | | |

| Net product sales | $ 1,119.0 | | $ 789.9 | | $ 2,884.3 | | $ 2,035.6 |

| Collaboration revenues | 3.7 | | 5.0 | | 11.9 | | 19.4 |

| Total revenues | 1,122.7 | | 794.9 | | 2,896.2 | | 2,055.0 |

| Operating expenses: | | | | | | | |

| Cost of revenues, excluding amortization of acquired intangible assets | 26.6 | | 13.0 | | 63.5 | | 31.5 |

| Research and development | 351.8 | | 250.0 | | 974.7 | | 757.5 |

| Acquired in-process research and development | 11.7 | | 0.3 | | 34.4 | | 0.4 |

| Selling, general, and administrative | 366.3 | | 291.6 | | 1,124.5 | | 854.4 |

| Amortization of acquired intangible assets | 35.0 | | 1.0 | | 51.5 | | 3.0 |

| Gain on sale of business, net of transaction costs | — | | — | | (28.6) | | — |

| Total operating expenses | 791.4 | | 555.9 | | 2,220.0 | | 1,646.8 |

| Operating income | 331.3 | | 239.0 | | 676.2 | | 408.2 |

| Other (expense) income : | | | | | | | |

| Interest expense | (0.3) | | — | | (3.2) | | — |

| Unrealized (loss) gain on equity investments | (52.3) | | 30.6 | | (25.8) | | (6.7) |

| Investment income and other, net | 5.0 | | 22.2 | | 45.5 | | 64.5 |

| Total other (expense) income, net | (47.6) | | 52.8 | | 16.5 | | 57.8 |

| Income before provision for income taxes | 283.7 | | 291.8 | | 692.7 | | 466.0 |

| Provision for income taxes | 77.2 | | 82.3 | | 143.9 | | 141.1 |

| Net income | $ 206.5 | | $ 209.5 | | $ 548.8 | | $ 324.9 |

| | | | | | | | |

| Earnings per share, basic | $ 2.03 | | $ 2.11 | | $ 5.43 | | $ 3.27 |

| Earnings per share, diluted | $ 1.96 | | $ 2.04 | | $ 5.26 | | $ 3.19 |

| | | | | | | | |

| Weighted average common shares outstanding, basic | 101.6 | | 99.4 | | 101.0 | | 99.3 |

| Weighted average common shares outstanding, diluted | 105.2 | | 102.5 | | 104.3 | | 102.0 |

| TABLE 2 |

| |

| NEUROCRINE BIOSCIENCES, INC. |

| CONDENSED CONSOLIDATED BALANCE SHEETS |

| (unaudited, in millions) |

| |

| | September 30, 2026 | | December 31, 2025 |

| Cash, cash equivalents, and marketable securities | $ 737.9 | | $ 1,480.4 |

| Accounts receivable | 957.3 | | 686.8 |

| Inventory | 66.1 | | 69.0 |

| Other current assets | 246.9 | | 286.5 |

| Total current assets | 2,008.2 | | 2,522.7 |

| Noncurrent inventory | 177.7 | | — |

| Noncurrent marketable securities | 51.8 | | 1,063.0 |

| Right-of-use assets | 437.2 | | 455.4 |

| Equity investments | 95.0 | | 120.8 |

| Property and equipment, net | 92.2 | | 89.8 |

| Intangible assets, net | 2,191.0 | | 4.7 |

| Goodwill | 500.6 | | 6.1 |

| Deferred tax assets | 11.8 | | 320.3 |

| Other noncurrent assets | 61.9 | | 48.7 |

| Total assets | $ 5,627.4 | | $ 4,631.5 |

| | | | |

| Total current liabilities | 984.6 | | 743.4 |

| Deferred tax liabilities | 105.0 | | — |

| Noncurrent operating lease liabilities | 392.3 | | 415.3 |

| Other noncurrent liabilities | 266.8 | | 219.7 |

| Stockholders' equity | 3,878.7 | | 3,253.1 |

| Total liabilities and stockholders' equity | $ 5,627.4 | | $ 4,631.5 |

| TABLE 3 |

| |

| NEUROCRINE BIOSCIENCES, INC. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS |

| (unaudited, in millions, except per share data) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| GAAP net income 1 | $ 206.5 | | $ 209.5 | | $ 548.8 | | $ 324.9 |

| Adjustments: | | | | | | | |

| Stock-based compensation expense | 54.3 | | 53.7 | | 176.5 | | 159.3 |

| Acceleration of stock-based compensation expense and related taxes 2 | — | | — | | 60.1 | | — |

| Acquisition-related employee compensation and severance costs | 16.7 | | — | | 38.6 | | — |

| Amortization of inventory fair value step-up 3 | 6.3 | | — | | 9.3 | | — |

| Amortization of acquired intangible assets 4 | 35.0 | | 1.0 | | 51.5 | | 3.0 |

| Acquisition/divestiture-related transaction and integration costs | 1.9 | | — | | 50.6 | | — |

| Gain on sale of business, net of transaction costs 5 | — | | — | | (28.6) | | — |

| Changes in fair values of equity investments 6 | 52.3 | | (30.6) | | 25.8 | | 6.7 |

| Other 7 | 1.9 | | 0.8 | | 3.2 | | 3.1 |

| Income tax effect related to reconciling items 8 | (28.2) | | (12.3) | | (91.9) | | (37.1) |

| Non-GAAP net income 1 | $ 346.7 | | $ 222.1 | | $ 843.9 | | $ 459.9 |

| | | | | | | | |

| Diluted earnings per share: | | | | | | | |

| GAAP | $ 1.96 | | $ 2.04 | | $ 5.26 | | $ 3.19 |

| Non-GAAP | $ 3.29 | | $ 2.17 | | $ 8.09 | | $ 4.51 |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Cost of Revenues: | | | | | | | |

| GAAP cost of revenues | $ 26.6 | | $ 13.0 | | $ 63.5 | | $ 31.5 |

| Adjustments: | | | | | | | |

| Acceleration of stock-based compensation expense and related taxes 2 | — | | — | | 1.8 | | — |

| Acquisition-related employee compensation and severance costs | — | | — | | 0.2 | | — |

| Amortization of inventory fair value step-up 3 | 6.3 | | — | | 9.3 | | — |

| Non-GAAP cost of revenues | $ 20.3 | | $ 13.0 | | $ 52.2 | | $ 31.5 |

| | | | | | | | |

| | | | |

| Research and Development: | | | | | | | |

| GAAP R&D | $ 351.8 | | $ 250.0 | | $ 974.7 | | $ 757.5 |

| Adjustments: | | | | | | | |

| Stock-based compensation expense | 24.7 | | 22.0 | | 76.4 | | 66.6 |

| Acceleration of stock-based compensation expense and related taxes 2 | — | | — | | 18.1 | | — |

| Acquisition-related employee compensation and severance costs | 8.9 | | — | | 13.9 | | — |

| Other 7 | 1.2 | | — | | 1.2 | | — |

| Non-GAAP R&D | $ 317.0 | | $ 228.0 | | $ 865.1 | | $ 690.9 |

| | | | | | | | |

| | | | |

| Selling, General, and Administrative: | | | | | | | |

| GAAP SG&A | $ 366.3 | | $ 291.6 | | $ 1,124.5 | | $ 854.4 |

| Adjustments: | | | | | | | |

| Stock-based compensation expense | 29.6 | | 31.7 | | 100.1 | | 92.7 |

| Acceleration of stock-based compensation expense and related taxes 2 | — | | — | | 40.2 | | — |

| Acquisition-related employee compensation and severance costs | 7.8 | | — | | 24.5 | | — |

| Acquisition/divestiture-related transaction and integration costs | 1.9 | | — | | 45.5 | | — |

| Other 7 | 0.4 | | 0.5 | | 1.5 | | 2.4 |

| Non-GAAP SG&A | $ 326.6 | | $ 259.4 | | $ 912.7 | | $ 759.3 |

| | | | | | | | |

| | | | |

| Amortization of Acquired Intangible Assets: | | | | | | | |

| GAAP amortization of acquired intangible assets | $ 35.0 | | $ 1.0 | | $ 51.5 | | $ 3.0 |

| Adjustments: | | | | | | | |

| Amortization of acquired intangible assets 4 | 35.0 | | 1.0 | | 51.5 | | 3.0 |

| Non-GAAP amortization of acquired intangible assets | $ — | | $ — | | $ — | | $ — |

| | | | | | | | |

| | | | | | | | |

| Gain on Sale of Business, Net of Transaction Costs: | | | | | | | |

| GAAP gain on sale of business, net of transaction costs | $ — | | $ — | | $ (28.6) | | $ — |

| Adjustments: | | | | | | | |

| Gain on sale of business, net of transaction costs 5 | — | | — | | (28.6) | | — |

| Non-GAAP gain on sale of business, net of transaction costs | $ — | | $ — | | $ — | | $ — |

| | | | | | | | |

| | | | | | | | |

| Other Income (Expense): | | | | | | | |

| GAAP other (expense) income, net | $ (47.6) | | $ 52.8 | | $ 16.5 | | $ 57.8 |

| Adjustments: | | | | | | | |

| Changes in fair values of equity investments 6 | 52.3 | | (30.6) | | 25.8 | | 6.7 |

| Acquisition/divestiture-related transaction and integration costs | — | | — | | 5.1 | | — |

| Other 7 | 0.3 | | 0.3 | | 0.5 | | 0.7 |

| Non-GAAP other income, net | $ 5.0 | | $ 22.5 | | $ 47.9 | | $ 65.2 |

| | |

| 1. | Includes the following expenses: |

| | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Milestones (R&D) | $ 10.0 | | $ 1.0 | | $ 32.9 | | $ 61.5 |

| Acquired in-process research and development (IPR&D) | $ 11.7 | | $ 0.3 | | $ 34.4 | | $ 0.4 |

| | |

| 2. | Relates to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction. |

| 3. | Relates to amortization expense associated with recording approximately $168 million of VYKAT XR inventory fair value step-up. |

| 4. | Primarily relates to amortization of acquired intangible assets associated with the recording of approximately $2.2 billion of intellectual property related to VYKAT XR, which will be amortized over 16 years. |

| 5. | Reflects a pre-tax gain, net of transaction costs, recognized on the sale of Neurocrine Group Limited in January 2026. |

| 6. | Reflects periodic fluctuations in the fair values of equity investments. |

| 7. | Reflects non-cash interest expense related to the Company's credit facility, legacy campus facility costs, net of sublease income, and other immaterial costs that management does not consider indicative of the Company's ongoing operating performance. |

| 8. | Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance. In addition, Non-GAAP tax expense may also be affected by certain non-recurring, non-operating, or discrete tax items. |

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-third-quarter-2026-financial-results-302926995.html

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.; Tony Jewell (Media), 858-617-7578, [email protected]; Todd Tushla (Investors), 858-617-7143, [email protected]

Resources

Email Alerts

2025 Annual Report

2026 Proxy Statement

Webcasts & Presentations

Prompts

Neurocrine Biosciences, Inc. (ticker NBIX), listed in United States.

ETFs Holding Neurocrine Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 6.51% 14,954 $ 2.481M Nov 17, 2026
BMED 2.30% 1,990 $ 328.967K Nov 16, 2026
AMID 2.04% 14,304 $ 2.37M Nov 18, 2026
CVSM 2.04% 11,525 $ 1.922M Jul 31, 2026
JMID 1.93% 2,742 $ 457.366K Jul 31, 2026
HELX 1.84% 3,058 $ 515.38K Jun 30, 2026
ILDR 1.56% 29,901 $ 4.943M Nov 16, 2026
SSMG 1.30% 250 $ 41.7K Jul 31, 2026
SHRT 1.23% 961 $ 158.863K Nov 17, 2026
CSMD 1.18% 32,094 $ 5.353M Jul 31, 2026
AGRW 1.11% 7,516 $ 1.254M Jul 31, 2026
JSMD 1.05% 66,455 $ 11.085M Jul 31, 2026
FEMG 0.98% 390 $ 65.729K Jun 30, 2026
JPEF 0.98% 113,897 $ 18.898M Nov 17, 2026
NDOW 0.98% 4,040 $ 680.881K Jun 30, 2026
JDOC 0.91% 540 $ 89.597K Nov 17, 2026
CLSE 0.82% 47,992 $ 7.392M Aug 31, 2026
DSTL 0.80% 101,238 $ 17.062M Jun 30, 2026
REGS 0.74% 2,840 $ 478.639K Jun 30, 2026
SYZ 0.63% 2,562 $ 431.787K Jun 30, 2026
FLDZ 0.50% 121 $ 20.393K Jun 30, 2026
BALQ 0.50% 1,285 $ 212.423K Nov 16, 2026
FEMV 0.50% 156 $ 26.291K Jun 30, 2026
ITAN 0.42% 3,094 $ 513.356K Nov 17, 2026
SMDX 0.41% 3,114 $ 514.775K Nov 17, 2026
SMIZ 0.38% 6,710 $ 1.034M Aug 31, 2026
JGRO 0.36% 196,058 $ 32.53M Nov 17, 2026
MCDS 0.33% 155 $ 25.718K Nov 17, 2026
JMEE 0.32% 54,365 $ 9.02M Nov 17, 2026
GVLU 0.32% 5,107 $ 844.238K Nov 17, 2026
FMDE 0.31% 136,513 $ 23.007M Jun 30, 2026
SXQG 0.27% 953 $ 161.438K Nov 12, 2026
JAVA 0.27% 122,868 $ 20.386M Nov 17, 2026
OASC 0.23% 1,380 $ 212.561K Aug 31, 2026
TMSL 0.21% 33,465 $ 5.64M Jun 30, 2026
SAGP 0.20% 929 $ 156.569K Jun 30, 2026
AVMC 0.19% 6,308 $ 1.043M Nov 16, 2026
BALI 0.19% 17,839 $ 2.949M Nov 16, 2026
BDVL 0.16% 17,542 $ 2.9M Nov 16, 2026
PINK 0.16% 3,162 $ 524.639K Nov 17, 2026
AVIE 0.15% 153 $ 25.292K Nov 16, 2026
FTQI 0.15% 8,874 $ 1.467M Nov 16, 2026
JUSA 0.15% 7,693 $ 1.276M Nov 17, 2026
FELC 0.13% 62,138 $ 10.472M Jun 30, 2026
REMC 0.11% 23 $ 3,876.31 Jun 30, 2026
FHEQ 0.11% 6,157 $ 1.027M Jul 31, 2026
HELO 0.11% 30,604 $ 5.078M Nov 17, 2026
FELV 0.11% 20,181 $ 3.401M Jun 30, 2026
FEAC 0.11% 162 $ 27.303K Jun 30, 2026
ESUM 0.10% 1,133 $ 188.984K Jul 31, 2026
IALT 0.10% 46,842 $ 7.743M Nov 16, 2026
HEQQ 0.10% 177 $ 29.368K Nov 17, 2026
FLSP 0.09% 5,146 $ 867.281K Jun 30, 2026
AFMC 0.09% 1,471 $ 243.171K Nov 16, 2026
JSTC 0.08% 1,395 $ 230.607K Nov 17, 2026
DFUV 0.08% 73,606 $ 12.469M Nov 12, 2026
DYNF 0.07% 186,417 $ 30.817M Nov 16, 2026
MSSM 0.06% 2,651 $ 408.334K Aug 31, 2026
ENHU 0.05% 29 $ 4,793.99 Nov 16, 2026
AVLC 0.05% 4,658 $ 770.014K Nov 16, 2026
DXUV 0.05% 18,294 $ 3.099M Nov 12, 2026
DFAC 0.04% 226,095 $ 38.3M Nov 12, 2026
AVSU 0.04% 1,220 $ 201.678K Nov 16, 2026
DCOR 0.03% 85,613 $ 14.503M Nov 12, 2026
VSLU 0.03% 974 $ 164.153K Jun 30, 2026
AVUS 0.03% 26,414 $ 4.366M Nov 16, 2026
DFAU 0.03% 22,011 $ 3.729M Nov 12, 2026
DFUS 0.02% 29,405 $ 4.981M Nov 12, 2026
EBI 0.02% 927 $ 142.786K Aug 31, 2026
WSGE 0.02% 70 $ 11.614K Nov 18, 2026
MSLC 0.01% 3,904 $ 601.333K Aug 31, 2026
DFAS 0.01% 25,691 $ 4.352M Nov 12, 2026
DFVX 0.01% 323 $ 54.716K Nov 12, 2026
FYEE 0.01% 110 $ 18.348K Jul 31, 2026
NTRL 0.00% 1,557 $ 0.00 Nov 16, 2026